Cadherin-6 in Focus: Existing Antibodies, Emerging Applications

Guest: Gary S. Firestein, MD <br> <article data-scroll-anchor="false" data-testid="conversation-turn-2" data-turn="assistant" data-turn-id="request-WEB:28ad69d6-f72b-40e5-8d3d-bd089d16951b-0" dir="auto" tabindex="-1"> <div> <div tabindex="-1"> <div> <div data-message-author-role="assistant" data-message-id="ab2fc424-fc4a-45a9-8b24-dddb56bb4dfb" data-message-model-slug="gpt-4o" dir="auto"> <div> <div> <p data-end="638" data-is-last-node="" data-is-only-node="" data-start="99">While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discusses the potential for cadherin-6 to become a useful target across multiple diseases. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.<...